Serimmune utilizes its Serum Epitope Repertoire Analysis (SERA) platform, which combines bacterial display peptide libraries and next-generation sequencing, to profile antibody responses and identify disease-specific epitopes. This technology addresses the need for comprehensive immune mapping to understand the biological processes behind diseases like Long COVID and other complex health conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for profiling antibody responses are limited in their ability to comprehensively map the interactions between the antibody repertoire and human disease. This makes it difficult to identify disease-specific epitopes and understand the biological processes underlying complex health conditions.
Solution
Serimmune offers a Serum Epitope Repertoire Analysis (SERA) platform that combines bacterial display peptide libraries and next-generation sequencing to broadly profile antibody repertoires. The SERA platform decodes the complexity of human antibody responses, empowering discovery projects through a universal serology assay that identifies disease-specific epitopes across proteins and entire proteomes. The platform applies machine learning and custom bioinformatics to reveal the diverse antigens stimulating immunity, providing a broad view of an individual’s environmental exposures and unique immune responses in disease and health. This technology enables researchers to identify candidate autoantigens for biomarker discovery, epitope and antigen discovery, infectious disease detection, and serological surveillance.
Target Audience
Serimmune's primary customers are researchers in academia, government, and industry focused on immuno-therapeutics, vaccines, and target discovery, as well as those studying oncology, autoimmune, infectious, and neurodegenerative diseases.
Features
- Bacterial display peptide library technology for comprehensive antibody repertoire profiling
- Next-generation sequencing for high-resolution epitope identification
- Proprietary informatics pipeline for identifying epitopes and motifs associated with disease
- State-of-the-art database with over 26,000 profiled antibody repertoires
- Applications in autoimmune disease, oncology, vaccine development, and infectious disease
- Discovery services for biomarker discovery and immune profiling
- Identification of both validated and potentially novel antigens in multiple autoimmune disorders
- Identification of candidate autoantigens that may be used as biomarkers for diagnosis, sub-typing, or monitoring in oncology
- Unbiased, whole proteome approach to epitope discovery for mapping the targets of humoral responses to vaccination
- Identification of the most significant antigens in infections for diagnostic and therapeutic target discovery
- Potential to enable dynamic monitoring and surveillance for hundreds of diseases in one assay